Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Clinical trial updates in prostate cancer at ESMO 2022

Aine Haran • 11 Sep 2022
ESMO 2022
Genitourinary Cancer Prostate Cancer
ARASENS PEACE-1 STAMPEDE

Aine Haran, BMBS, MRCS, The Christie and Salford Royal Hospitals, Manchester, UK, discusses updates in prostate cancer clinical trials at ESMO 2022, including STAMPEDE (NCT00268476), PEACE-1 (NCT01957436), and ARASENS (NCT02799602). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Aine Haran

1:45
STAMPEDE: Post-hoc analysis of nodal metastases
Aine Haran • 11 Sep 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals